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ABSTRACT Tobacco plants were genetically transformed
with the gene encoding hepatitis B surface antigen (HBsAg)
linked to a nominally constitutive promoter. Enzyme-linked
immunoassays using a monoclonal antibody directed against
human serum-derived HBsAg revealed the presence ofHBsAg
in extracts of transformed leaves at levels that correlated with
mRNA abundance. This suggests that there were no major
inherent limitations of transcription or translation of this
foreign gene in plants. Recombinant HBsAg was purified from
transgenic plants by immunoafflnity chromatography and ex-
amined by electron microscopy. Spherical particles with an
average diameter of 22 nm were observed in negatively stained
preparations. Sedimentation of transgenic plant extracts in
sucrose and cesium chloride density gradients showed that the
recombinant HBsAg and human serum-derived HBsAg had
similar physical properties. Because the HBsAg produced in
transgenic plants is antigenically and physically similar to the
HBsAg particles derived from human serum and recombinant
yeast, which are used as vaccines, we conclude that transgenic
plants hold promise as low-cost vaccine production systems.
Hepatitis B virus infection is one ofthe most widespread viral
infections of humans and causes acute and chronic hepatitis
and hepatocellular carcinoma (1). The infectious viral particle
(Dane particle) is a 43-nm double-shelled sphere that consists
of a core containing the 3.2-kilobase (kb) DNA genome
bound to the core protein, surrounded by the viral envelope
containing phospholipids and the major surface antigen [hep-
atitis B surface antigen (HBsAg)] (2). In addition to Dane
particles, the serum of infected individuals also contains
22-nm subviral particles in great excess over virions. These
noninfectious particles contain the elements of the viral
envelope, including the major 24-kDa peptide that occurs in
glycosylated and unglycosylated forms (2).
Because the host range of hepatitis B virus is limited to
humans and chimpanzees, and since the virus cannot be
propagated in cell culture, HBsAg for use in vaccines was
purified from the serum of infected individuals until a recom-
binant form (rHBsAg) was produced in yeast (3). The immu-
nogenic yeast-derived rHBsAg occurs in the form of spher-
ical particles with an average diameter of 17 nm. Integration
of the peptides into the phospholipid-containing particles
greatly enhances their immunogenic properties (4). Subse-
quent work showed that the peptides present in the yeast-
derived particles were much less extensively disulfide-linked
than in the human material but that such linking could be
induced in vitro (5).
Intramuscular injection of serum-derived HBsAg or yeast-
derived rHBsAg in healthy individuals results in effective
immunization and protection from viral infection (6, 7). In
many areas ofthe developing world, however, the expense of
immunization programs for large segments of the population
is prohibitive. This has led us to attempt the expression of
rHBsAg in plants with the hope of developing a less expen-
sive production system. Further, we hope to find a way to
present the rHBsAg in edible plant tissues in a form that
would be useful as an oral vaccine. In this paper we describe
the transformation oftobacco with the gene encoding HBsAg
and its expression in leaf tissue in the form of an antigenic
spherical particle with an average diameter of 22 nm. This
plant-derived rHBsAg is directly analogous to the rHBsAg
from yeast that is now used for commercial vaccines. We
view this as a successful first step in a long-term project
dedicated to developing technologies for low cost "edible
vaccines" for the developing world.
MATERIALS AND METHODS
Construction of Plasmids for Plant Transformation. The
HBsAg coding region on the Pst I/HindIII fragment from
pMT-SA (kindly provided by Li-he Guo, Chinese Academy
of Sciences) was subcloned into pBluescript KS (Stratagene)
to form pKS-HBS. The HBsAg gene in pKS-HBS was
opened 116 base pairs (bp) 3' to the termination codon with
BstBI and the resulting ends were blunted by filling with
Klenow enzyme and dCTP/dGTP. The entire coding region
was then excised 16 bp upstream ofthe Pst I site with BamHI.
pBI121 (ref. 8; obtained from Clontech) was digested with
Sac I and the ends were blunted with mung bean nuclease.
The GUS coding region was then released with BamHI and
the vector was isolated. The HBsAg coding fragment was
ligated into the GUS-less pBI121 to yield pHB101 (Fig. 1),
where its expression is driven by the cauliflower mosaic virus
(CaMV) promoter derived from pBI121.
The CaMV 35S promoter with duplicated enhancer linked
to the tobacco etch virus (TEV) 5' nontranslated leader
sequence, which acts as a translational enhancer (9), was
excised from pRTL2-GUS (10) as follows. pRTL2-GUS was
digested with Nco I and the ends were blunted with mung
bean nuclease. The promoter-leader fragment was then re-
leased by digestion with HindIII. pHB101 was digested with
HindIII and Sma I to release the 35S promoter fragment, and
the vector was purified. The promoter-leader fragment was
then ligated into the HindIII/Sma I-digested pHB101 to yield
pHB102 (Fig. 1). The HBsAg coding region lies upstream of
the nopaline synthase terminator in both constructs. The
plasmids contain the left and right border regions, which
denote the limits of the DNA that is integrated into the plant
genomic DNA via Agrobacterium tumefaciens-mediated
transformation, as well as the neomycin phosphotransferase
gene, which allows selection with kanamycin.
Plant Transformation. Agrobacterium strain LBA4404
cells were transformed by the direct method (11) with the
plasmids prepared from Escherichia coli clones, and the
Abbreviations: CaMV, cauliflower mosaic virus; HBsAg, hepatitis B
surface antigen; rHBsAg, recombinant HBsAg; TEV, tobacco etch
virus.
§To whom reprint requests should be addressed.
11745
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 89 (1992)
RB ATG
Hindill PstI XbaI Sinai
Pst Sph Oh Eco R Eoo RI
Hind 11PtI XalSm
I~p I| pHB 101
pHB 102
-35-ual Enhaor FEW
Hind III P.t I XhoI E co RI
Sph
FIG. 1. Structure of plasmids pHB101 and pHB102. The constructs carry the left and right borders (LB, RB) of the transferred DNA that
demarcates the sequences that are incorporated into the plant genomic DNA via Agrobacterium-mediated transformation. The HBsAg coding
region lies downstream of the CaMV 35S promoter in pHB101 and is followed by the nopaline synthase (NOS) terminator. In pHB102, the 35S
promoter is replaced by a modified CaMV 35S promoter containing a duplicated transcriptional enhancer region, linked to the TEV 5'
nontranslated leader (TL). Restriction endonuclease cleavage sites are indicated. Blunt-ended ligation has removed the Nco I site at the 3' end
of the leader sequence.
structure of the plasmids was verified by restriction diges-
tion. Tobacco (Nicotiana tabacum cv. Samsun) was trans-
formed by cocultivating leaf discs (12) with Agrobacterium
strains transformed with pHB101 or pHB102. Shoots were
generated from transformed callus selected on medium con-
taining 0.2 mg ofkanamycin per ml and 0.2 mg of cefotaxime
per ml. Shoots were rooted in medium containing 0.1 mg of
kanamycin per ml, transplanted to soil, and watered with
one-half strength Hoagland medium.
Analysis of RNA ftom Transformed Tobacco. Total RNA
from leaves of plants transformed with pHB101 was isolated
as described (13). The RNA was denatured with formalde-
hyde, fractionated on 1% agarose gels (5 Iug per lane), blotted
to nylon, and probed with 32P-labeled random-primed DNA
using a 700-bp BamHI/Acc I fragment from pKS-HBS that
includes most of the coding region for HBsAg. Blots were
hybridized at 680C in 0.25M sodium phosphate, pH 7.0/1 mM
EDTA/7% SDS, washed with 40mM sodium phosphate, pH
7.0/5% SDS at 68C, and exposed to X-Omat AR film for 4
hr.
Analysis of Protein from Transformed Tobacco. Protein was
extracted from leaf tissues by homogenization with a Ten-
Broek ground glass homogenizer (clearance, 0.15 mm) in 5
volumes of buffer containing 20 mM sodium phosphate (pH
7.0), 0.15 M NaCl, 20 mM sodium ascorbate, 0.1% Triton
X-100, and 0.5mM phenylmethylsulfonyl fluoride at 40C. The
homogenate was centrifuged at 1000 x g for 5 min, and the
supernatant was centrifuged at 27,000 x g for 15 min. The
27,000 x g supernatant was centrifuged at 100,000 X g for 1
hr, and the pellet was resuspended in extraction buffer.
Protein in the different fractions was measured by the
Coomassie dye-binding assay (Bio-Rad). HBsAg was as-
sayed with the Auszyme monoclonal kit (Abbott), using the
positive control (HBsAg derived from human serum) as a
standard. The positive control was diluted to give HBsAg
levels of0.09-1.8 ng per assay, and the absorbance at 492 nm
after color development gave a linear relationship in this
range.
Ininiunoanly Purifcation of HBsAg from Transgenic
Tobacco. Monoclonal antibody against HBsAg (clone
ZMHB1) was obtained from Zymed Laboratories. The im-
munogen source for this antibody is human serum. The
antibody was bound to Affi-Gel Hz hydrazide gel (Bio-Rad)
according to the instructions supplied with the kit. Soluble
material that was resuspended from the 100,000 x g pellet
was made to 0.5 M NaCl and mixed with the immobilized
antibody-gel by end-over-end mixing for 16 hr at 40C. The gel
was washed with 10 volumes of 10 mM sodium phosphate,
pH 7.0/0.5 M NaCl, and 10 volumes of 10 mM sodium
phosphate, pH 7.0/0.15 M NaCl, and bound HBsAg was
eluted with 0.2 M glycine (pH 2.5). The eluate was immedi-
ately neutralized with Tris base, and particles were pelleted
at 109,000 x g for 1.5 hr at 50C. The pelleted material was
negatively stained with phosphotungstic acid and visualized
with transmission electron microscopy using a Phillips CM10
microscope.
Sucrose and CsCI Gradient Analyss of HloAg from Tranw
geni Tobacco. Extracts of leaf tissues were made as de-
scribed above and 0.5 ml of the 27,000 x g supernatants was
layered on linear 11-ml 5-30%o sucrose gradients made in 10
mM sodium phosphate, pH 7.0/0.15 M NaCl or discontinu-
ous 12-ml CsCl gradients (1.1-1.4 g/ml) made in 10 mM
sodium phosphate at pH 7.0 (3 ml each of 1.1, 1.2, 1.3, and
1.4 g of CsCI per ml). Positive control HBsAg from the
Auszyme kit was also layered on separate gradients. The
sucrose gradients were centrifuged in a Beckman SW41Ti
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FIG. 2. HBsAg mRNA and protein levels in transgenic tobacco
plants. (A) Total RNA from wild-type untransformed or independent
transgenic tobacco lines carrying either the pHB101 or the pHB102
construct was hybridized with a probe specific for the HBsAg coding
region. (B) Protein extracts fiom the same leaves were tested for
HBsAg with the Auszyme monoclonal kit (Abbott), and HBsAg
levels were quantified using a standard curve of human serum-
derived HBsAg. Numbers: 1, wild-type control plant; 2-6, indepen-
dent transformants harboring the construct in pHB101; 7-9, inde-
pendent transformants harboring the construct in pHB102.
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FIG. 3. (Upper) Electron micrograph of immunoaffinity purified rHBsAg. HBsAg from a transgenic tobacco plant harboring construct
pHB102 was purified by immunoaffinity chromatography, negatively stained with phosphotungstic acid, and visualized by transmission electron
microscopy. (Bar = 100 nm.) (Lower) Histogram generated by measuring the diameters of the particles observed in the representative field.
rotor at 33,000 rpm for 5 hr at 50C and fractionated into 1-ml
fractions while monitoring the A280. The CsCl gradients were
centrifuged in a Beckman SW40Ti rotor at 30,000 rpm for 25
hr at 50C and fractionated into 1.0-ml fractions. HBsAg in the
gradient fractions was assayed using the Auszyme kit as
described above. The density of gradient fractions was mea-
sured by weighing aliquots with an analytical balance.
RESULTS AND DISCUSSION
The plasmid HB101 (Fig. 1) was constructed by inserting the
coding region for HBsAg from pMT-SA between the BamHI
and Sac I sites in the plant transformation vector pBI121 after
removal of the GUS coding region. In this construct the
expression of HBsAg is driven by the CaMV 35S promoter.
A modification of pHB101 was made by inserting the CaMV
35S promoter with dual transcriptional enhancer linked to the
TEV 5' nontranslated leader (10) in the place of the original
35S promoter to form pHB102 (Fig. 1). The TEV leader acts
as a translational enhancer to increase the amount of protein
made using a given amount of template mRNA (9).
The plasmids were used to transform tobacco by the leaf
disc method using Agrobacterium, and regenerated kanamy-
cin-resistant transformants were analyzed by hybridizing
RNA samples with a labeled probe encompassing the coding
region of the HBsAg gene. Fig. 2A shows the results of an
experiment where selected transformants harboring either
the pHB101 or the pHB102 construct and a wild-type control
were probed. The signals were variable between transform-
ants, as expected due to effects of position of insertion into
the genomic DNA and differing copy number. The transcripts
from the pHB101 transformants (Fig. 2A, lanes 2-6) were
~=1.2 kb in length by comparison with RNA standards
(H.S.M., unpublished data), which is consistent with the
expected size. The pHB102 transcripts were slightly larger
(Fig. 2A, lanes 7-9), owing to the 5' addition of the TEV
leader sequence. The nontransformed control leafRNA (Fig.
2A, lane 1) showed no detectable signal at this stringency of
hybridization. Thus, mRNA that hybridizes specifically with
HBsAg probe was present in the leaves of selected trans-
formants, and there is no inherent transcriptional limitation to
the expression of HBsAg in tobacco leaves.
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Using the HBsAg assay kit, we tested leaf extracts for the
presence of material that reacts specifically with monoclonal
antibody to serum-derived HBsAg. Fairly low levels were
observed for the pHB101 transformants, ranging from 2 to 6
ng/mg of soluble protein (Fig. 2B, nos. 2-6). The pHB1O2
transformants showed substantially greater levels ofHBsAg,
ranging up to 66 ng/mg of soluble protein (Fig. 2B, nos. 7-9).
The reaction was specific because wild-type tobacco showed
no detectable HBsAg (Fig. 2B, no. 1). The levels of HBsAg
observed in the individual transformants were roughly pro-
portional to the levels of specific mRNA encoding HBsAg for
a given construct. The pHB102 transformants, containing the
5' TEV leader, showed much higher accumulations ofHBsAg
for a given amount of mRNA than did the pHB101 trans-
formants (Fig. 2). The translational enhancement observed in
mRNAs carrying the TEV leader appears to involve a cap-
independent competition for translation initiation factors (9).
HBsAg from human serum occurs as -22-nm spherical
particles, consisting of protein embedded in a phospholipid
bilayer. Since rHBsAg from plasmid-transformed yeast also
occurs as particles of a similar size class, we sought evidence
that the recombinant material in tobacco is present as parti-
cles. We observed that 95% of the HBsAg in the 27,000 x g
supernatants of transgenic tobacco leaf extracts pelleted at
200,000 x g for 30 min (H.S.M., unpublished data), suggest-
ing a particle form. We purified HBsAg by immunoaffinity
chromatography using a monoclonal antibody raised against
human serum-derived HBsAg. Inspection of this material by
negative staining and transmission electron microscopy re-
vealed the presence of particles ranging in diameter between
10 and 40 nm (Fig. 3). Most of the particles were between 16
and 28 nm (Fig. 3 Lower); the average diameter was 22 rm.
These are very similar to the particles observed in human
serum (2), although we observed no rods. The rHBsAg
particles from yeast occur in a range of sizes with a mean of
17 nm (3). We conclude that the rHBsAg made in transgenic
tobacco retains the capacity for self-association and thus has
the physical properties of human serum-derived HBsAg and
rHBsAg from yeast, both of which are highly immunogenic
in the particle form.
We obtained further evidence of particle behavior from
sedimentation and buoyant density studies of transgenic
tobacco leaf extracts. Fig. 4 shows a sucrose gradient profile
of HBsAg activity from transgenic tobacco harboring the
construct in pHB102. The plant-derived HBsAg sedimented
with a peak near the 60S ribosomal subunit, and the serum-
derived material sedimented in a somewhat sharper peakjust
slightly slower. These data are consistent with the finding
that human HBsAg sediments at 55 S (14). The observation
that the plant material sedimented slightly faster and with a
broader peak than the human HBsAg is also consistent with
the larger mean size of the plant particles and wider range of
sizes (Fig. 3). The buoyant density of the rHBsAg from
transgenic tobacco in CsCl was found to be -1.16 g/ml (Fig.
5), whereas the human particle showed a density of about
1.20 g/ml. Thus, the rHBsAg from transgenic tobacco ex-
hibits sedimentation and density properties that are very
similar to the subviral particles obtained from human serum.
Importantly, HBsAg in the particle form is found to be much
more immunogenic than that in the form of the peptide alone
(4).
The subcellular localization ofthe HBsAg in our transgenic
plants has not been characterized. Particles are observed in
the lumen of the endoplasmic reticulum in infected liver cells
(15) and appear to be secreted by the constitutive secretory
pathway. The peptides contain two signal sequences, one
N-terminal and one internal, that together determine a trans-
membrane orientation of the molecules (2). Whether the
rHBsAg particles in leaf cells are secreted to the extracellular
space or retained within the cytoplasm is a question that
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FIG. 4. Sucrose density gradient sedimentation of HBsAg from
transgenic tobacco. Soluble fractions from a transformant harboring
the pHB102 construct or human serum-derived HBsAg were sedi-
mented in 5-30%o sucrose gradients, fractionated, and assayed for
HBsAg. The solid curve represents the absorbance profile at 280 nm
of the plant extract. The top of the gradient is at the left; positions
of the 40S and 60S ribosomal subunits are indicated. a, HBsAg in
transgenic plant extract; v, HBsAg in serum-derived material; solid
line, absorbance of tobacco leaf extract at 280 rm.
needs to be addressed. Although the HBsAg coding region is
part of a larger open reading frame in the viral genome (2), the
lack of the pre-S peptide does not alter the formation of
particles in transfected mammalian cells (16) or yeast (3). Our
construct also contains no pre-S sequences and is thus similar
to that used in those studies. We were unable to analyze the
size of the HBsAg peptides produced in transgenic tobacco
because the monoclonal antibodies that we used failed to
recognize the SDS-denatured peptides on SDS/PAGE blots.
The antibodies did recognize undenatured HBsAg in dot blots
ofleaf extracts or blots ofwhole leaves or seedlings, however
(H.S.M., unpublished data).
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FIG. 5. Buoyant density in CsCl of HBsAg from transgenic
tobacco. Supernatant fractions of transgenic tobacco harboring
construct pHB102 and human serum-derived HBsAg were banded in
a 1.1-1.4 g/ml CsCl gradient. Fractions were assayed for HBsAg
activity. m, HBsAg in plant extract; v, HBsAg in serum-derived
material; o, density of gradient fractions.
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In conclusion, we have shown that HBsAg can be ex-
pressed in plant tissues via stable transformation with foreign
DNA. Furthermore, the rHBsAg from transgenic tobacco is
recognized specifically by monoclonal antibodies directed
against human serum-derived HBsAg and is processed prop-
erly after translation so that the antigenic particle form is
observed. These studies indicate the feasibility of expression
of foreign antigens in plants for possible use as oral vaccines.
Presently, the maximal levels of HBsAg we have found in
transgenic plants represent 0.01% of the soluble leaf pro-
tein. This is an inadequate level for the efficient use of plants
as production systems for rHBsAg for vaccine use. Further
studies must be done to increase the accumulation ofHBsAg,
such as using other transcriptional regulatory elements to
increase mRNA levels. The processing of the HBsAg pep-
tides in plant tissues must also be examined, specifically with
regard to glycosylation and intermolecular disulfide bonding.
The HBsAg system may be useful for determining the fea-
sibility of targeting foreign antigens to specific subcellular
compartments.
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